Recent developments in gastrointestinal prokinetic agents

Bibliography

• Ouyang A, Locke GR. Overview of neurogastroenterology. Gastrointestinal motility and functional GI disorders: classification, prevalence, and epidemiology. Gastroenterol Clin North Am 2007;36:485-98
   PubMedGoogle Scholar
• Videlock EJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am 2007;36:665-85
   PubMedGoogle Scholar
• Rao SSC. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am 2007;36:687-711
   PubMedGoogle Scholar
• Richter JE. The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment. Gastroenterol Clin North Am 2007;36:577-99
   PubMed Web of Science ®Google Scholar
• Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol Clin North Am 2007;36:619-47
   PubMed Web of Science ®Google Scholar
• Kehlet H, Holte K. Review of postoperative ileus. Am J Surg 2001;182(Suppl 5A):S3-10
   PubMed Web of Science ®Google Scholar
• Deane A, Chapman MJ, Fraser RJ, et al. Mechanisms underlying feed intolerance in the critically ill: implications for treatment. World J Gastroenterol 2007;13:3909-17
   PubMedGoogle Scholar
• Reddymasu SC, Soykan I, Mccallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102:2036-45
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement. A review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3:138-48
   PubMedGoogle Scholar
• IDdB3: Drug report for mosapride. Available from: http://iddb3.com/iddb3/ iddb3_2/reports.display?id=3658& template=Drug&i_query_id=9139813 [Last accessed 14 January 2007]
   Google Scholar
• IDdB3: Drug report for renzapride. Available from: http://iddb3.com/ iddb3/iddb3_2/reports.display? id=4211&template=Drug&i_query_id=9139814&i_clear_trail=Y [Last accessed 14 January 2008]
   Google Scholar
• Meyers NL, Hickling RI. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res 2007;35:848-66
   PubMed Web of Science ®Google Scholar
• IDdB3: Drug report for prucalopride. Available from: http://iddb3.com/ iddb3/iddb3_2/reports.display? id=15716&template=Drug&i_query_id=9139815&i_clear_trail=Y [Last accessed 14 January 2008]
   Google Scholar
• Giger R, Mattes H, Pfannkuche H-J. Case history on tegaserod (Zelnorm/Zelmac). Ann Rep Med Chem 2007;42:195-209
   Google Scholar
• Chen T-Y, Rosow CE, Serradell N, et al. Methylnaltrexone bromide: opioid receptor antagonist treatment of constipation treatment of postoperative ileus. Drugs Future 2007;32:771-5
   Google Scholar
• IDdB3: Drug report for alvimopan. Available from: http://iddb3.com/iddb3/iddb3_2/reports.display?id=9447& template=Drug&i_query_id=9139816 [Last accessed 25 January 2008]
   Google Scholar
• Hawkyard CV, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother 2007;59:347-58
   PubMedGoogle Scholar
• Crowell MD, Harris LA, Dibaise JK, Olden KW. Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs 2007;8:66-70
   PubMed Web of Science ®Google Scholar
• Glaxo Group Ltd UK. Preparation of benzofuran-7-carboxamide derivatives as 5-HT4 agonists. WO2007048643; 2007
   Google Scholar
• Glaxo Group Ltd UK. Preparation of 5-amino-6-bromo-N-[[1-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-piperidinyl]methyl]-3,4-dihydro-2H-chromene-8-carboxamide as 5-HT4 receptor agonist. WO2007096352; 2007
   Google Scholar
• Glaxo Group Ltd UK. 4-Aminobenzamide derivatives as 5-HT4 receptor agonists for the treatment of gastrointestinal, neurological and cardiovascular disorders. WO2007068739; 2007
   Google Scholar
• IDdB3: Drug report for TDI-5108. Available from: http://iddb3.com/iddb3/iddb3_2/reports.display?id=54688& template=Drug&i_query_id=9139841 [Last accessed 14 January 2008]
   Google Scholar
• Theravance, Inc., USA. Preparation of N-(tropan-3-yl)indazole-3-carboxamides as 5-HT4 receptor agonists for treating reduced motility of gastrointestinal tract. WO2005080389; 2005
   Google Scholar
• Theravance, Inc., USA. Preparation of quinolinone-carboxamide compounds as 5-HT4 receptor agonists. US2005228014; 2005
   Google Scholar
• Theravance, Inc., USA. Preparation of quinolinone-carboxamides 5-HT4 receptor agonist compounds. US20060100236; 2006
   Google Scholar
• Theravance, Inc., USA. Preparation of azabicyclooctyl quinolononecarboxamides as serotonin 5-HT4 receptor agonists. US20060100426; 2006
   Google Scholar
• Theravance, Inc., USA. Preparation of therapeutic indazole-carboxamide compounds as 5-HT4 receptor agonists. US20060135764; 2006
   Google Scholar
• Theravance, Inc., USA. Preparation of piperidinylmethylpiperidinylmethyl benzimidazolecarboxamides as serotonin 5-HT4 receptor agonists. WO2006127815; 2006
   Google Scholar
• Theravance, Inc., USA. Preparation of azabicyclooctyl benzimidazolonecarboxamides as serotonin 5-HT4 receptor agonists. US20060276482; 2006
   Google Scholar
• Theravance, Inc., USA. Preparation of quinolinone-carboxamides 5-HT4 receptor agonist compounds. WO2006094063; 2006
   Google Scholar
• Theravance, Inc., USA. Preparation and formulation of nortropane benzoimidazolone-carboxamide derivatives as 5-HT4 receptor agonists. US2007117796; 2007
   Google Scholar
• Theravance, Inc., USA. Preparation of crystalline form of an indazolecarboxamide compound. US2006183901; 2006
   Google Scholar
• Theravance, Inc., USA. Crystalline form of a quinolinone-carboxamide compounds and their preparation, pharmaceutical compositions, and their 5-HT4a binding affinity. WO2006108127; 2006
   Google Scholar
• Pfizer Japan, Inc./Pfizer, Inc. Preparation of benzimidazolones having 5-HT4 receptor agonistic activity. WO2005021539; 2006
   Google Scholar
• Pfizer, Inc., Japan. Preparation of benzimidazolone-1-carboxylic acid derivatives as selective 5-HT4 receptor agonists. US2005277672; 2005
   Google Scholar
• Pfizer Japan, Inc./Pfizer, Inc. Quinolonecarboxylic acid compounds, their preparation, pharmaceutical compositions, and 5-HT4 receptor agonistic activity. WO2005049608; 2005
   Google Scholar
• Pfizer Japan, Inc./Pfizer, Inc. A preparation of 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives, useful as 5-HT4 receptor agonists. WO2005073222; 2005
   Google Scholar
• Pfizer Japan, Inc./Pfizer, Inc. Preparation of 4-amino-5-halogeno-benzamides as 5-HT4 receptor agonists for the treatment of gastrointestinal, CNS, neurological and cardiovascular disorders. WO2005092882; 2005
   Google Scholar
• Pfizer Japan, Inc./Pfizer, Inc. Preparation of benzoisoxazole derivatives as 5-HT4 receptor agonists. WO2006090224; 2006
   Google Scholar
• Pfizer Japan, Inc./Pfizer, Inc. Synthesis of oxyindolyl piperidine derivatives as 5-HT4 receptor agonists. WO2006090279; 2006
   Google Scholar
• Pfizer Japan, Inc./Pfizer, Inc. Preparation of indazolecarboxamide derivatives as 5-HT4 receptor agonists. WO2007010390; 2007
   Google Scholar
• Toga T, Kohmura Y, Kawatsu R. The 5-HT4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci 2007;105:207-10
   PubMedGoogle Scholar
• Becker DP, Flynn DL, Moormann AE, et al. Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists. J Med Chem 2006;49:1125-39
   PubMed Web of Science ®Google Scholar
• Aryx Therapeutics, USA. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders. WO2005068461; 2005
   Google Scholar
• Aryx Therapeutics, USA. Preparation of pyridyl- and pyridonylcarbonylaminopiperidines for the treatment of gastrointestinal disorders. WO2007005951; 2007
   Google Scholar
• Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30-8
   PubMed Web of Science ®Google Scholar
• Dainippon Pharmaceutical Co. Ltd, Japan. Preparation of 2-alkoxy-6-amino-5-halo-N-(1-substituted-4-piperidinyl)pyridine-3-carboxamide derivatives as 5-HT4 receptor agonists, pharmaceutical compositions containing them, and their use. JP2005082508; 2005
   Google Scholar
• IDdB3: Drug report for pumosetrag. Available from: http://iddb3.com/ iddb3/iddb3_2/reports.display? id=9983&template=Drug&i_query_id=9139818&i_clear_trail=Y [Last accessed 14 January 2008]
   Google Scholar
• Evangelista S. Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Investig Drugs 2007;8:416-22
   PubMed Web of Science ®Google Scholar
• Adolor Corp, USA. Preparation of substituted piperidine compounds as opioid antagonists. US20050203123; 2005
   Google Scholar
• Adolor Corp, USA. Preparation of substituted epoxymorphinans as opioid receptor modulators. US20060063792; 2006
   Google Scholar
• Adolor Corp, USA. Preparation of quinolizidines and octahydropyridopyrazines as opioid antagonists. WO2007050802; 2007
   Google Scholar
• Theravance, Inc., USA. Preparation of 8-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as μ-opioid receptor agonists. WO2007103187; 2007
   Google Scholar
• Cremonini F, Camilleri M, McKinzie S, et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100:652-63
   PubMed Web of Science ®Google Scholar
• Morton MF, Barrett TD, Yan W, et al. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide. J Pharmacol Exp Ther 2007;323:562-9
   PubMedGoogle Scholar
• Nguyen NQ, Fraser RJ, Chapman MJ, et al. Feed intolerance in critical illness is associated with increased basal and nutrient-stimulated plasma cholecystokinin concentrations. Crit Care Med 2007;35(1):82-8
   PubMed Web of Science ®Google Scholar
• Jarvie EM, North Laidler VJ, Corcoran S, et al. Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Br J Pharmacol 2007;150:455-62
   PubMed Web of Science ®Google Scholar
• Peeters TL. New motilin agonists: a long and winding road. Neurogastroenterology 2006;18:1-5
   PubMed Web of Science ®Google Scholar
• IDdB3: Drug report for mitemcinal. Available from: http://iddb3.com/ iddb3/iddb3_2/reports.display? id=7668&template=Drug&i_query_id=9139838&i_clear_trail=Y [Last accessed 14 January 2008]
   Google Scholar
• Park M-I, Ferber I, Camilleri M, et al. Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006;18:28-36
   PubMedGoogle Scholar
• IDbD3: Drug report for KOS-2187. Available from: http://iddb3.com/ iddb3/iddb3_2/reports.display? id=39753&template=Drug&i_query_id=9139843&i_clear_trail=Y [Last accessed 14 January 2008]
   Google Scholar
• Kosan Biosciences, Inc., USA. Preparation of 11-deoxy-6,9-ether erythromycin derivatives as antibacterial and prokinetic agents and used to treat disorders of gastric motility. WO2005018577; 2005
   Google Scholar
• Kosan Biosciences, Inc., USA. Preparation of 9-des-oxo-erythromycin compounds as prokinetic agents. WO2005060693; 2005
   Google Scholar
• Kosan Biosciences, Inc., USA. Preparation of motilide derivatives for use as prokinetic agents in the treatment of diseases of impaired gastric mobility. WO2006127252; 2006
   Google Scholar
• Bristol-Myers-Squibb Co., USA. Compounds useful as motilin agonists in treating disorders of gastrointestinal motility. WO2005027637; 2005
   Google Scholar
• Li JJ, Chao H-G, Wang H, et al. Discovery of a potent and novel motilin agonist. J Med Chem 2004;47:1704-8
   PubMed Web of Science ®Google Scholar
• Glaxo Group Ltd, UK. Preparation of heteroarylbenzylpiperazines as GPR38 receptor agonists. WO2007007018; 2007
   Google Scholar
• Glaxo Group Ltd, UK. Preparation of benzylpiperazine derivatives as agonists of GPR38 receptors. WO2007012479; 2007
   Google Scholar
• Peeters TL. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. Curr Opin Pharmacol 2006;6:553-8
   PubMed Web of Science ®Google Scholar
• IDdB3: Drug report for capromorelin. Available from: http://iddb3.com/ iddb3/iddb3_2/reports.display? id=19610&template=Drug&i_query_id=9139844&i_clear_trail=Y [Last accessed 27 March 2008]
   Google Scholar
• Kitazawa T, De Smet B, Verbeke K, et al. Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut 2005;54:1078-84
   PubMed Web of Science ®Google Scholar
• Elixir Pharmaceuticals, Inc., USA. Growth-hormone secretagogues for the treatment of disorders of the stomach, intestine or duodenum. WO2006023608; 2006
   Google Scholar
• Sapphire Therapeutics, Inc., USA. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues, and therapeutic use. WO2006020930; 2006
   Google Scholar
• IDdB3: Drug report for TZP-101. Available from: http://iddb3.com/ iddb3/iddb3_2/reports.display? id=50157&template=Drug&i_query_id=9139845&i_clear_trail=Y [Last accessed 14 January 2008]
   Google Scholar
• Venkova K, Fraser G, Hoveyda HR, Greenwood-Van Meerveld B. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci 2007;52:2241-8
   PubMed Web of Science ®Google Scholar
• Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a Phase I, first-in-human study. J Clin Pharmacol 2008;48:193-202
   PubMed Web of Science ®Google Scholar
• Tranzyme Pharma, Inc., Canada. Preparation and methods of using macrocyclic modulators of the ghrelin receptor. WO2006009645; 2006
   Google Scholar
• Tranzyme Pharma, Inc., Canada. Preparation of macrocyclic modulators of the ghrelin receptor. WO2006009674; 2006
   Google Scholar
• Glaxo Group Ltd, UK. Piperazine derivatives and their preparation, pharmaceutical compositions, and agonistic activity of growth hormone secretagogue (GHS) receptors for the treatment of gastrointestinal disorders. WO2006010629; 2006
   Google Scholar
• Glaxo Group Ltd, UK. Preparation of piperazine derivatives as growth hormone secretagogue receptor agonists. WO2007113202; 2007
   Google Scholar
• Glaxo Group Ltd, UK. Preparation of aryl and heteroaryl sulfonamide amino acid derivatives as growth hormone secretagogue receptor agonists. WO2007118852; 2007
   Google Scholar
• Heightman TD, Scott JS, Longley M, et al. Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part 1: lead identification. Bioorg Med Chem Lett 2007;17:6584-7
   PubMedGoogle Scholar
• Witherington J, Abberley L, Briggs MA. Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: lead optimisation. Bioorg Med Chem Lett 2008;18:2203
   PubMedGoogle Scholar
• Bristol-Myers-Squibb Co., USA. A process for preparation of tetrazole-derived compounds, useful as growth hormone secretagogues. US20050096466; 2005
   Google Scholar
• Bristol-Myers-Squibb Co., USA. Preparation of azoles as growth hormone secretagogues. US20060079562; 2006
   Google Scholar
• Bristol-Myers-Squibb Co., USA. A preparation of pyrrolidine derivatives, useful as growth hormone secretagogues. US20050154043; 2005
   Google Scholar
• Hernandez AS, Cheng PTW, Musial CM, et al. Discovery, synthesis, and structure-activity studies of tetrazole-based growth hormone secretagogues. Bioorg Med Chem Lett 2007;17:5928-33
   PubMedGoogle Scholar
• Li J, Chen SY, Li JJ, et al. Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl) carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2-benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180). J Med Chem 2007;50:5890-3
   PubMedGoogle Scholar
• Zentaris GMBH, Germany/Le Centre National De La Recherche Scientifique/University of Montpeller I/University Of Montpeller II. Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors, their preparation, pharmaceutical compositions, and use in therapy. WO2007020013; 2007
   Google Scholar
• Zentaris GMBH, Germany/Le Centre National De La Recherche Scientifique/University of Montpeller I/University Of Montpeller II. Preparation of tryptophan-derived triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors. US20070037857; 2007
   Google Scholar
• Demange L, Boeglin D, Moulin A, et al. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor 1. J Med Chem 2007;50:1939-57
   PubMed Web of Science ®Google Scholar
• Moulin A, Demange L, Ryan J, et al. Trisubstituted 1,2,4-triazoles as ligands for the ghrelin receptor: on the significance of the orientation and substitution at position 3. Bioorg Med Chem Lett 2008;18:164-8
   PubMed Web of Science ®Google Scholar
• Deghenghi R. Pseudopeptides growth hormone secretagogues. US20050245457; 2005
   Google Scholar
• Societe De Conseils De Recherches Et D'Applications Scientifiques SAS. Preparation Of Growth Hormone Secretagogues. WO2007014258; 2007
   Google Scholar
• Societe De Conseils De Recherches Et D'Applications Scientifiques SAS. Composition and methods for stimulating gastrointestinal motility using ghrelin analogs. WO2007041278; 2007
   Google Scholar
• Societe De Conseils De Recherches Et D'Applications Scientifiques SAS. Preparation of therapeutic analogs of ghrelin active at the GHS receptor. WO2007038678; 2007
   Google Scholar
• Harris LA, Crowell MD. Drug evaluation: linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007;9:403-10
   PubMed Web of Science ®Google Scholar
• Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
   PubMed Web of Science ®Google Scholar
• Microbia, Inc., USA. Peptides activating guanylate cyclase C receptor for use in treatment of gastrointestinal disorders. WO2005087797; 2005
   Google Scholar
• Microbia, Inc., USA. Methods and compositions using guanylate cyclase C (GC-C) receptor-activating peptides for the treatment of gastrointestinal disorders and other conditions. WO2005016244; 2005
   Google Scholar
• Microbia, Inc., USA. Methods and heat-stable enterotoxin-derived peptide compositions for activating guanylate cyclase C and treatment of gastrointestinal disorders. WO2007022531; 2007
   Google Scholar
• Microbia, Inc., USA. Guanylin variants as guanylate cyclase C receptor agonist peptides for the treatment of gastrointestinal disorders. WO2007101158; 2007
   Google Scholar
• Microbia, Inc., USA. ST peptide variants as guanylate cyclase C receptor agonist peptides for the treatment of gastrointestinal disorders. WO2007101161; 2007
   Google Scholar
• Callisto Pharmaceuticals, Inc., USA. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis. US7041786; 2006
   Google Scholar
• Thielemans L, Depoortere I, Perret J, et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther 2005;313:1397-405
   PubMed Web of Science ®Google Scholar
• Lamian V, Rich A, Ma Z, et al. Characterization of agonist-induced motilin receptor trafficking and its implications for tachyphylaxis. Mol Pharmacol 2006;69:109-18
   PubMedGoogle Scholar
• Janssen Pharmaceutica NV (Belg). Imidazoles and their use as CCK1 modulators. WO2005063716; 2005
   Google Scholar